Furthermore, pathophysiological differences in the amplification of chromosome 11q13 and microsatellite instability in advanced esophageal cancer might contribute to beneficial effects of the OS rather than the PFS parameters, when treated with PD-1/PD-L1 inhibitors [9]. Here, CD274 is linked to esophageal cancer.